PA8651401A1 - Formas de dosificacion oral solidas que contienen una dosis baja de estradiol - Google Patents

Formas de dosificacion oral solidas que contienen una dosis baja de estradiol

Info

Publication number
PA8651401A1
PA8651401A1 PA20058651401A PA8651401A PA8651401A1 PA 8651401 A1 PA8651401 A1 PA 8651401A1 PA 20058651401 A PA20058651401 A PA 20058651401A PA 8651401 A PA8651401 A PA 8651401A PA 8651401 A1 PA8651401 A1 PA 8651401A1
Authority
PA
Panama
Prior art keywords
dosage forms
solid oral
oral dosage
estradiol
forms containing
Prior art date
Application number
PA20058651401A
Other languages
English (en)
Spanish (es)
Inventor
Adrian Funke
Torsten Wagner
Kristina Mueller
Christian Zurth
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PA8651401A1 publication Critical patent/PA8651401A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PA20058651401A 2004-11-02 2005-11-02 Formas de dosificacion oral solidas que contienen una dosis baja de estradiol PA8651401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078014 2004-11-02

Publications (1)

Publication Number Publication Date
PA8651401A1 true PA8651401A1 (es) 2006-12-07

Family

ID=34928627

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058651401A PA8651401A1 (es) 2004-11-02 2005-11-02 Formas de dosificacion oral solidas que contienen una dosis baja de estradiol

Country Status (21)

Country Link
EP (1) EP1814526A2 (pt)
JP (1) JP2008518895A (pt)
KR (1) KR20070085558A (pt)
CN (1) CN101094656A (pt)
AR (1) AR053650A1 (pt)
AU (1) AU2005300658A1 (pt)
BR (1) BRPI0517940A (pt)
CA (1) CA2585095A1 (pt)
CR (1) CR9112A (pt)
CU (1) CU20070094A7 (pt)
EA (1) EA013262B1 (pt)
GT (1) GT200500315A (pt)
IL (1) IL182635A0 (pt)
MX (1) MX2007005281A (pt)
NO (1) NO20072704L (pt)
PA (1) PA8651401A1 (pt)
PE (1) PE20061126A1 (pt)
TW (1) TW200621312A (pt)
UY (1) UY29185A1 (pt)
WO (1) WO2006048261A2 (pt)
ZA (1) ZA200705012B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
KR20080047959A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
US20130140210A1 (en) 2010-04-15 2013-06-06 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
CN112516149B (zh) * 2020-07-21 2023-07-18 南方医科大学 苯甲酸雌二醇或其药物可接受盐在制备抗冠状病毒的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125071C (pt) * 1963-12-24
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
ATE532521T1 (de) * 2000-12-15 2011-11-15 Novo Nordisk Femcare Ag Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis
FR2823976A1 (fr) * 2001-04-25 2002-10-31 Theramex Nouvelle composition hormonale et son utilisation
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
JP2004155779A (ja) * 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd 更年期症の予防・治療用経口組成物

Also Published As

Publication number Publication date
NO20072704L (no) 2007-05-29
MX2007005281A (es) 2008-03-11
WO2006048261A2 (en) 2006-05-11
CR9112A (es) 2007-11-23
EA013262B1 (ru) 2010-04-30
AU2005300658A1 (en) 2006-05-11
UY29185A1 (es) 2006-05-31
CN101094656A (zh) 2007-12-26
EA200700979A1 (ru) 2007-10-26
ZA200705012B (en) 2008-10-29
AR053650A1 (es) 2007-05-16
JP2008518895A (ja) 2008-06-05
TW200621312A (en) 2006-07-01
CA2585095A1 (en) 2006-05-11
WO2006048261A3 (en) 2006-09-21
IL182635A0 (en) 2007-07-24
GT200500315A (es) 2006-06-06
PE20061126A1 (es) 2006-11-11
BRPI0517940A (pt) 2008-10-21
KR20070085558A (ko) 2007-08-27
EP1814526A2 (en) 2007-08-08
CU20070094A7 (es) 2009-09-08

Similar Documents

Publication Publication Date Title
AR109263A2 (es) Composición que comprende moxidectina
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
DOP2009000155A (es) Derivados de hetero-pentaciclo-fenilo fusionados, composicion farmaceutica que los comprende y usos para preparar un medicamento util para el tratamiento de una condicion mediada por p38
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
PA8651401A1 (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
RU2007122391A (ru) S-миртазапин для лечения приливов
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
CL2004000984A1 (es) Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica.
CL2004000767A1 (es) Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos.
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
NI201000185A (es) Métodos para usar el factor liberador de corticotropina para el tratamiento del cáncer.
AR048355A1 (es) Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen
AR057161A1 (es) Metodos y formas de dosificacion de derivados de benzisoxazol con mejor eficacia